Our previous study showed that these VSV-carried p53 transgenes not only enhanced VSV anticancer abilities through the introduction of functional p53 into cancer cells with defective tumor suppression activity, but also through the downregulation of antiviral signaling in cancer cells (37). This evidence concerns the gene TP53 and neoplasm.